Related Experiment Video
Updated: Jun 23, 2026

12:24
Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
Published on: July 17, 2012
A microcomputed tomography guided fluorescence tomography system for small animal molecular imaging
Dax Kepshire1, Niculae Mincu, Michael Hutchins
1Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire 03755, USA. dax.s.kepshire@dartmouth.edu
The Review of Scientific Instruments
|May 2, 2009
Summary
A novel multimodality imaging system combines fluorescence tomography (FT) with x-ray microcomputed tomography (microCT) for enhanced preclinical cancer research. This system offers synergistic data for tumor microenvironment studies and treatment efficacy assessments.
Area of Science:
- Biomedical Engineering
- Medical Imaging
- Preclinical Research
Background:
- Multimodality imaging offers synergistic information for complex biological studies.
- Integrating fluorescence tomography (FT) with x-ray microcomputed tomography (microCT) can improve spatial resolution and functional information.
- Existing systems may lack the sensitivity or integration needed for detailed preclinical cancer research.
Purpose of the Study:
- To develop and validate a prototype small animal imaging system coupling FT with microCT.
- To leverage microCT images as prior spatial information for FT.
- To enable overlay of FT images onto microCT images for comprehensive analysis.
Main Methods:
- Designed a noncontact FT system utilizing single photon counting for maximal sensitivity.
- Employed five parallel detector locations for simultaneous fluorescence and transmitted excitation signal sampling.
- Conducted calibration, linearity tests, and phantom studies, including imaging protoporphyrin IX.
Main Results:
- The prototype system successfully integrated FT and microCT.
- Phantom studies demonstrated the system's calibration and linearity performance.
- The system is validated for in vivo use to image endogenous protoporphyrin IX, a tumor marker.
Conclusions:
- The developed multimodality imaging system provides synergistic information for preclinical cancer research.
- The system is ready for in vivo application, particularly for studying tumor microenvironments and treatment efficacy.
- This technology holds significant potential for advancing cancer therapeutics research.

